Released Jun 10, 2021, before the open
10-Q filed Jun 10, 2021, 71 days after period end · 0001785530-21-000026
Q1 2021 · 10-Q
Revenue—
Net Income-$7.44M-$7.44M N/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$83.36-$83.36 N/M vs Q1 2020no prior Q4 2020 on file
Operating Income-$7,452,000N/M
Operating Cash Flow-$7,326,000N/M
Free Cash Flowderived-$7,339,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Net Income | -$7.44M | -$3.83M |
| EPS Diluted | -$83.36 | -$4.58 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR